The loss of CRISPR Therapeutics under GAAP for 6 months of 2020 amounted to $149,387 million, an increase of 46.3% compared to $102,107 million in the previous year. Revenue decreased by 3 times to $201k compared to $646k a year earlier.
The loss of CRISPR Therapeutics under GAAP for 6 months of 2020 amounted to $149,387 million, an increase of 46.3% compared to $102,107 million in the previous year. Revenue decreased by 3 times to $201k compared to $646k a year earlier. 
crisprtx.gcs-web.com
English (US) 